Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial)
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: No pharmacological therapies are approved for non‐alcoholic fatty liver disease (NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has been developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this prospective, single‐arm study is to evaluate the efficacy of luseogliflozin on hepatic fat content and glycated hemoglobin (HbA1c) in T2DM patients with NAFLD. Methods: Forty T2DM patients with NAFLD were treated with luseogliflozin 2.5 mg/day for 24 weeks. Primary end‐points were changes in HbA1c and hepatic steatosis evaluated by magnetic resonance imaging–hepatic fat fraction from baseline. Secondary end‐points were changes in metabolic and hepatic function‐related parameters, including hepatic fibrosis markers (Fibrosis‐4 index, NAFLD fibrosis score, type IV collagen 7S. and Wisteria floribunda agglutinin‐positive Mac‐2 binding protein). Results: Not only HbA1c and transaminase activities but also hepatic fat content were significantly decreased after 24 weeks of therapy with luseogliflozin. The reduction of hepatic fat content was significantly correlated with the reduction of alanine aminotransferase. Although hepatic fibrosis markers were unchanged, serum ferritin levels reduced and serum albumin significantly increased after the treatment. Conclusion: Luseogliflozin can be a novel promising agent for the treatment of T2DM patients with NAFLD. Prospective randomized controlled trials are warranted to confirm this impact of luseogliflozin onT2DM with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Introduction of fast MR imaging in the assessment of hepatic steatosis
Fishbein, M. H., Gardner, K. G., Potter, C. J., Schmalbrock, P., & Smith, M. A. (1997) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(96)00224-x · Cited by 226
Cited by
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S., Patel, J., Kellogg, T. A., Abu Dayyeh, B. K., & Hurt, R. T. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 285
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Self-citationGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Arai, T., Atsukawa, M., Tsubota, A., Ono, H., Kawano, T., Yoshida, Y., Okubo, T., Hayama, K., Nakagawa‐Iwashita, A., Itokawa, N., et al. (2022) · JGH Open · doi:10.1002/jgh3.12780 · Cited by 34
Metadata
- Authors
- Sumida, Y., Murotani, K., Saito, M., Tamasawa, A., Osonoi, Y., Yoneda, M., & Osonoi, T.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2018-08-31
- Volume
- 49
- Issue
- 1
- Pages
- 64-71
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W2884837248
- Cited by
- 106
- References
- 5
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial). https://app.cochat.ai/papers/10.1111/hepr.13236
- The paper
- Sumida, Y., Murotani, K., Saito, M., Tamasawa, A., Osonoi, Y., Yoneda, M., & Osonoi, T. (2019). Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial). Hepatology Research. https://doi.org/10.1111/hepr.13236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.